← brief for 2026-10-14 · Slowing decline

Aldosterone-mineralocorticoid receptor signaling and residual cardiorenal risk in type 2 diabetes.

Paper No results yet Peer reviewed

Key takeaways

This review looks at how a hormone called aldosterone affects the heart and kidneys in people with type 2 diabetes. It summarizes what is known so far. It is a review of existing studies, not a new trial with results. It helps explain why some risk remains even with good treatment.

Who did this work

Zhao S · Wang C · Ou Y

Source

Paper · PubMed, the drug frontier · 2026 Oct 14
https://pubmed.ncbi.nlm.nih.gov/42873316/